Managing Vomiting on Mounjaro (tirzepatide for T2D): The HealthRX.com Step-by-Step Protocol

How common is vomiting on Mounjaro?

The Mounjaro label reports adverse reactions from a pool of two placebo-controlled trials in adults with type 2 diabetes, one as monotherapy (SURPASS-1) and one in combination with basal insulin with or without metformin (SURPASS-5), covering 718 patients treated with Mounjaro for a mean of 36.6 weeks [1]. Vomiting was reported by 2% of the 235 patients on placebo, 5% of those on 5 mg, 5% on 10 mg and 9% on 15 mg [1]. Nausea was more common than vomiting at every dose: 4% on placebo, 12% on 5 mg, 15% on 10 mg and 18% on 15 mg [1].

Severe gastrointestinal reactions were uncommon in that adult pool: 0.9% on placebo compared with 1.3% on 5 mg, 0.4% on 10 mg and 1.2% on 15 mg [1]. Any gastrointestinal adverse reaction was reported by 20.4% of placebo patients and by 37.1%, 39.6% and 43.6% of those on 5, 10 and 15 mg, and GI reactions led to discontinuation in 0.4% of placebo patients versus 3.0%, 5.4% and 6.6% [1].

Other trials put those figures in context. In SURPASS-2, an open-label 40-week trial of 1,879 adults with type 2 diabetes on metformin, vomiting was reported by 6% to 10% of those on tirzepatide (5, 10 or 15 mg) versus 8% on semaglutide 1 mg [2]. A 2024 review of tirzepatide in type 2 diabetes describes the adverse events as mostly mild to moderate, with gastrointestinal events including nausea, diarrhea, decreased appetite and vomiting the most common [3]. A 2025 systematic review and network meta-analysis of 39 studies covering 33,354 people with overweight or obesity and without diabetes found that tirzepatide was associated with an increased risk of vomiting [4].

In a separate cardiovascular outcomes trial of 6,647 adults with type 2 diabetes and established cardiovascular disease, vomiting was reported by 12% of those exposed to Mounjaro [1]. The label cautions that adverse reaction rates from different trials cannot be directly compared [1].

When during treatment does vomiting happen?

The label states that the majority of reports of nausea, vomiting and diarrhea occurred during dose escalation and decreased over time [1]. The label's starting dose and escalation schedule are to be followed to reduce the risk of gastrointestinal adverse reactions [1]. The label describes that pattern without attaching a fixed number of days to it.

The dosing levers the label provides

Mounjaro starts at 2.5 mg injected subcutaneously once weekly [1]. The label allows an increase of 2.5 mg after at least 4 weeks on the current dose, and only if additional glycemic control is needed [1]. The maximum is 15 mg weekly in adults and 10 mg weekly in patients 10 years of age and older [1].

If a dose is missed, the label says to take it as soon as possible within 4 days (96 hours); if more than 4 days have passed, skip the missed dose and take the next one on the regularly scheduled day [1]. The weekly day can be moved as long as two doses are at least 3 days (72 hours) apart [1].

Dehydration and kidney risk

The label's acute kidney injury warning describes postmarketing reports, some requiring hemodialysis, mostly in patients who had gastrointestinal reactions leading to dehydration such as nausea, vomiting or diarrhea [1]. The label tells clinicians to monitor renal function in patients who report reactions that could lead to volume depletion, especially during dose initiation and escalation [1].

When vomiting points to something else

Acute pancreatitis. The label says to observe patients for signs and symptoms of acute pancreatitis, which may include persistent or severe abdominal pain, sometimes radiating to the back, and which may or may not be accompanied by nausea or vomiting [1].

Gallbladder disease. Acute gallbladder disease (cholelithiasis, biliary colic, cholecystectomy) was reported by 0.6% of Mounjaro-treated patients and 0% of placebo-treated patients in adult placebo-controlled trials, and the label says gallbladder studies and clinical follow-up are indicated if cholelithiasis is suspected [1].

Gastroparesis. Mounjaro is not recommended in patients with severe gastroparesis [1].